Financial News

Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,022.87 +5.09 (+0.50%)

Official Closing Price Updated: 7:00 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

99 100 Next >

Peering Into Eli Lilly's Recent Short Interest ↗

September 18, 2025

Via Benzinga

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Via Benzinga

Here's Why Novo Nordisk and Eli Lilly Could Still Be Absurdly Underrated Stocks to Buy Today ↗

September 18, 2025

Medicare and Medicaid coverage of GLP-1 weight loss drugs could be just what the doctor ordered for these two struggling stocks.

Via The Motley Fool

Topics Government

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs ↗

September 18, 2025

The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.

Via Benzinga

Topics ETFs

Eli Lilly Says Its Obesity Pill Topped Novo Nordisk’s Oral Drug In Late-Stage Diabetes Trial ↗

September 17, 2025

Via Stocktwits

Why Is Eli Lilly’s Stock Slipping Premarket? ↗

September 17, 2025

Via Stocktwits

Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside ↗

September 16, 2025

Via Stocktwits

Novo Nordisk Pops 8% On 'Significant' Weight Loss For Oral Wegovy ↗

September 18, 2025

Novo Nordisk stock surged Thursday after its oral version of Wegovy helped patients lose a "significant" amount of weight.

Via Investor's Business Daily

Novo Nordisk's Wegovy Outperforms Eli Lilly's Tirzepatide In Reducing Risk Of Heart Attack, Stroke, And Death: Study ↗

September 18, 2025

Novo Nordisk's Wegovy cut cardiovascular risks more than tirzepatide in real-world data from patients with obesity and heart disease.

Via Benzinga

Why Is Everyone Talking About Novo Nordisk Stock? ↗

September 18, 2025

Competition in various directions is affecting the company's fastest-growing product.

Via The Motley Fool

3 Dividend Growth Stocks You Can Buy and Forget About ↗

September 18, 2025

These stocks have been raising their payouts for years and they're likely going to continue doing so for the foreseeable future.

Via The Motley Fool

Topics Economy

Krispy Kreme Jumps After Hours Following Kash Patel's Stake Reveal ↗

September 18, 2025

Krispy Kreme's stock rose 3.81% after hours on Wednesday, following FBI Director Kash Patel's testimony about his stock purchase, despite a 68.28% drop in 2025.

Via Benzinga

1 Mega-Cap Stock with Impressive Fundamentals and 2 We Question

September 18, 2025

"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their...

Via StockStory

Topics Artificial Intelligence

Novo Nordisk Stock Jumps After-Hours On Wegovy Pill Breakthrough As Weight-Loss War With Eli Lilly Heats Up ↗

September 17, 2025

The Danish drugmaker has already filed the once-daily pill with U.S. regulators, aiming for the first FDA-approved oral GLP-1 treatment for obesity.

Via Stocktwits

FBI Director Kash Patel Bought 2 Stocks In 2025 — One's Already A Meme Favorite ↗

September 17, 2025

FBI Director Kash Patel was asked about two stocks he bought earlier this year by a member of Congress on Wednesday and gave a surprising answer. The transactions come as members of Congress are...

Via Benzinga

Why Novo Nordisk Stock Popped Today ↗

September 17, 2025

Novo Nordisk lost half its value over the past year. Is it cheap enough to buy now?

Via The Motley Fool

Congressional Trading Report: Rep. David Taylor Sold Over $2K In Alphabet Stock ↗

September 17, 2025

Via Benzinga

GSK To Pour $30 Billion Into US R&D, Manufacturing Over Five Years ↗

September 17, 2025

GSK will invest $30 billion in U.S. R&D and manufacturing, including a new biologics factory, AI upgrades, and expanded drug and device capabilities.

Via Benzinga

Topics Artificial Intelligence

Could This Eli Lilly Oral Pill Be Key To Significant Weight Loss? ↗

September 17, 2025

Eli Lilly's orforglipron showed significant weight loss, improved blood sugar, and reduced inflammation in adults with obesity or overweight in a Phase 3 trial.

Via Benzinga

Apple To Rally More Than 28%? Here Are 10 Top Analyst Forecasts For Wednesday ↗

September 17, 2025

Via Benzinga

This FedEx Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗

September 17, 2025

Via Benzinga

Dow Futures Stall Ahead Of Fed’s Interest Rate Decision Today: WDAY, MSFT, GOOGL, NVDA Among Stocks To Watch ↗

September 17, 2025

While Dow Jones futures were up 0.03% at the time of writing, the S&P 500 futures fell 0.07%.

Via Stocktwits

Topics ETFs Economy Government

GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America ↗

September 16, 2025

The plan includes $1.2 billion for a new biologics factory in Upper Merion, Pennsylvania, along with AI upgrades and expanded drug production across existing U.S. sites.

Via Stocktwits

Topics Artificial Intelligence Government World Trade

Why Eli Lilly Stock Was a Winner Today ↗

September 16, 2025

A news article implied that the company might have an advantage in the weight loss drug race.

Via The Motley Fool

Novo Nordisk Navigates a GLP-1 Gold Rush: Soaring Obesity Drug Sales Clash with Revised Outlook Amidst Mounting Competition

September 16, 2025

Copenhagen, Denmark – Pharmaceutical giant Novo Nordisk (NYSE: NVO) has reported a robust second quarter for 2025, with impressive revenue and net income figures largely propelled by the formidable...

Via MarketMinute

Topics Earnings Economy Intellectual Property

FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims ↗

September 16, 2025

The FDA finds Eli Lilly's video on Zepbound and Mounjaro misleading, citing omissions of serious risks.

Via Benzinga

Eli Lilly To Invest $5 Billion In New Virginia Manufacturing Facility To Support Cancer Drugs Manufacturing ↗

September 16, 2025

Eli Lilly plans a $5 billion Virginia facility to expand drug production, create 650 jobs, and use advanced tech for cancer and autoimmune treatments.

Via Benzinga

Wegovy's Next Step: Novo Nordisk Eyes Approval for Higher-Dose Treatment ↗

September 16, 2025

Novo Nordisk plans to seek FDA approval for a high-dose Wegovy, matching Eli Lilly's Zepbound with another weight-loss option for patients.

Via Benzinga

3 Undervalued Healthcare Stocks to Buy Now While They're Cheap ↗

September 16, 2025

In an otherwise hot stock market, healthcare stocks are underperforming.

Via The Motley Fool

Forecasting The Future: 10 Analyst Projections For Eli Lilly ↗

September 16, 2025

Via Benzinga

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Financial News

Eli Lilly (NY:LLY)

All News about Eli Lilly

Popular Pages